Related Experiment Videos
Effect of a perfluorocarbon emulsion (Fluosol-DA) on reticuloendothelial system clearance function
American Journal of Hematology
|January 1, 1984
Summary
Fluosol-DA, an oxygen transport emulsion, temporarily suppresses the reticuloendothelial system (RES) in rats, reducing the clearance of transfused red blood cells. This RES blockade effect is dose-dependent and transient.
Area of Science:
- Immunology
- Pharmacology
- Biomedical Engineering
Background:
- The reticuloendothelial system (RES) plays a crucial role in clearing foreign substances and aged cells from circulation.
- Perfluorocarbon emulsions are investigated for various biomedical applications, including oxygen transport.
- Understanding the impact of Fluosol-DA on RES function is essential for its clinical safety and potential therapeutic uses.
Purpose of the Study:
- To investigate the effect of Fluosol-DA on the reticuloendothelial system (RES) function.
- To quantify the RES-blocking capacity of Fluosol-DA in vivo.
- To compare Fluosol-DA's RES-blocking effect with other agents.
Main Methods:
- Human erythrocytes were transfused into rats to assess blood clearance.
- Blood clearance was measured by determining the percentage of 20-hour blood recovery and 51Cr half-life (t1/2) of transfused erythrocytes.
- Fluosol-DA was administered at a dose of 30 ml/kg, with comparisons to saline, soybean oil emulsion, and ethyl palmitate.
Main Results:
- Fluosol-DA significantly increased the 20-hour blood recovery and 51Cr t1/2 survival of human red cells compared to saline.
- The RES suppression induced by Fluosol-DA was transient, with no detectable effect seven days post-administration.
- Fluosol-DA demonstrated a RES-blocking effect approximately three times greater than a soybean oil emulsion and less potent than ethyl palmitate.
Conclusions:
- Fluosol-DA transiently suppresses RES clearance function in rats.
- The RES-blocking effect of Fluosol-DA is dose-dependent and reversible.
- Fluosol-DA warrants further investigation as a potential therapeutic RES blocker for immune cytopenias in humans.